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ABSTRACT
Hematopoietic system-specific miHAs are ideal targets for adoptive immunotherapy after allogeneic HLA
(alloHLA)-matched SCT. Adoptive immunotherapy with cytotoxic T cells targeting hematopoietic system-
specific miHAs restricted by alloHLA molecules is an attractive strategy to treat relapsed hematologic
malignancies after HLA-mismatched SCT. As a proof of principle, we exploited 2 new strategies to generate
alloHLA-A2-restricted miHA-specific T cells from HLA-A2neg donors using a HLA/miHA multimer-guided
approach. In one strategy, autologous DCs coated with HLA-A2/miHA complexes were used for in vitro
generation of miHA-specific T cells fromHLA-A2neg male donors. In the other strategy, miHA-specific T cells
were directly isolated from the peripheral blood of HLA-A2neg parous females with HLA-A2pos offspring. Both
methods introduced recombinant HLA-A2/miHA complexes as the sole allogeneic target antigen. However,
neither method yielded high avidity miHA-specific T cells or prevented the emergence of peptide-dependent
promiscuous T cells. The latter T cells resembled miHA-specific T cells so closely with regard to tetramer
binding and cytokine production that only extensive testing at a clonal level revealed their nonspecific nature.
Therefore, promiscuity of the alloHLA-A2 T cell repertoire of HLA-A2neg individuals hampers in vitro
generation of genuine miHA-specific T cells and limits its use for adoptive immunotherapy after HLA-A2
mismatched SCT.
© 2007 American Society for Blood and Marrow Transplantation
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Allogeneic (allo) SCT is a well established treat-
ent for a variety of hematologic malignancies [1].
he ideal stem cell (SC) donor in terms of reliable
ngraftment and minimal GVHD is a genotypically
LA-identical sibling [2]. Such donors are available
or approximately 30% of patients [3]. The remaining
atients are transplanted with SCs from haploidentical
amily donors or (partially) HLA-matched unrelated
onors. SCT across HLA mismatches is feasible using mcell depletion [4,5]. However, the risk of leukemia
elapse is high after T cell-depleted SCT [6,7] due to
he absence of a graft-versus-leukemia (GVL) effect
ediated by donor T cells [8,9].
The potency of the GVL effect is illustrated by the
uccessful application of DLIs to treat relapsed leuke-
ia after alloSCT [10]. Because the donor lympho-
ytes have not been selected for preferential reactivity
gainst malignant cells, DLI therapy is often accom-
anied by GVHD. High rates of GVHD-associated
orbidity and mortality limit the use of DLI after
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L. E. M. Oosten et al.152LA-mismatched SCT [11]. A potential approach to
he treatment of relapsed leukemia after HLA-mis-
atched SCT comprises adoptive immunotherapy
ith leukemia-speciﬁc cytotoxic T cells. In this set-
ing, a patient’s mismatched HLA molecules are used
s antigen-presenting molecules for hematopoietic
ystem-speciﬁc antigens to generate non-self (allo)
LA-restricted T cells from the SC donor. Such
lloHLA-restricted T cells should theoretically lyse a
atient’s hematopoietic cells only, including leukemic
ells. Nonhematopoietic tissues that do not express
he relevant antigen and graft-derived donor hemato-
oietic cells that lack the appropriate HLA restriction
olecule should not be lysed. Previous studies have
escribed in vitro generation of this type of T cells
ecognizing malignancy-associated or hematopoietic
ystem-speciﬁc antigens presented by alloHLA mole-
ules [12-18].
However, existing protocols for the generation of
lloHLA-restricted cytotoxic T cells are complex and
ot clinically applicable, requiring the use of alloge-
eic cell lines as APCs or cloning by limiting dilution.
hus there is a real need for a simple, robust protocol
or the generation of alloHLA-restricted T cells in-
orporating APCs that meet the requirements of good
anufacturing practice.
To address this issue, we explored two new and
ifferent strategies to generate alloHLA-A2-restricted
ematopoietic system-speciﬁc CD8T cells. The ﬁrst
trategy was based on a recent study by Savage et al
14]. We explored the feasibility of using autologous
Cs coated with recombinant trimeric HLA-A2/pep-
ide complexes to stimulate alloHLA-A2-restricted
D8 T cells from HLA-A2neg donors. DCs are the
ost specialized APCs for induction and expansion of
D8 T cells [19,20]. Recombinant HLA-A2 com-
lexes contained the previously described immuno-
enic T cell epitopes of the miHAs HA-1 or HA-2
21]. Expression of HA-1 and HA-2 is restricted to the
ematopoietic system, including leukemic cells and their
rogenitors [22-24]. Moreover, emergence of HA-1-
nd HA-2-speciﬁc T cells was shown to coincide with
R of relapsed leukemia or multiple myeloma after
LIs from HLA-matched HA-1- or HA-2-mis-
atched SC donors [25]. In addition, HA-1-speciﬁc
ytotoxic T cells signiﬁcantly inhibit human leukemia
utgrowth in a translational NOD/SCID model [26].
hus, HA-1 and HA-2 are suitable targets for adop-
ive immunotherapy after HLA-matched HA-1-
nd/or HA-2-mismatched SCT.
In the second strategy, we examined the feasibility
f using HLA-A2/miHA tetramers to directly isolate
lloHLA-A2-restricted HA-1- or HA-2-speciﬁc
D8 T cells from PBMCs of HLA-A2neg parous
emale donors who had delivered 1 HLA-A2pos
hild. Subsequent speciﬁcity and functional studies of
n vitro induced and ex vivo isolated alloHLA-A2- *estricted HA-1A2 or HA-2A2 tetramer binding CD8
cells were performed at both the polyclonal and
lonal levels.
ETHODS
lood Donors
Two healthy HLA-A2neg male blood donors with
o record of prior blood transfusions were selected on
he basis of successful in vitro generation of HLA-A2/
A-1-speciﬁc T cells in earlier experiments [13]. Five
ealthy HLA-A2neg multiparous female blood donors
ere selected on the basis of high levels of HLA-
2-speciﬁc antibody after delivery of an HLA-A2pos
A-2pos child. HLA typing of the donors is listed in
able 1. Informed consent was obtained according to
nstitutional guidelines. PBMCs were isolated by Fi-
oll-Isopaque density gradient centrifugation and
tored in liquid nitrogen.
ynthetic Peptides and HLA-A2/miHA Peptide
omplexes
HA-1, HA-2, HY, and CMV peptides were syn-
hesized according to their reported sequences [27-30]
nd referred to as pHA-1, etc, in the ﬁgures. Biotin-
lated recombinant HLA-A2/peptide complexes were
enerated as described previously [31] and used as
onomers for the coating of artiﬁcial antigen-pre-
enting constructs (aAPC), as streptavidin (Molecular
robes, Leiden, the Netherlands) bound trimers for
he coating of DCs, or as tetramers (peptideA2) for
nalysis of miHA-speciﬁc T cells. The speciﬁcity and
electivity of HLA-A2/miHA peptide tetramers have
een extensively tested and reported [32]. HPLC sep-
ration of a peptide pool eluted from HLA-A2 was
erformed using an 0.1% heptaﬂuorobutyric acid gra-
ient as described previously [33].
iHA-specific Polyclonal T Cell Lines and Clones,
D4 Th Cells, and DCs
In vitro generation of miHA-speciﬁc T cell lines
nd clones and CD4 Th cells is documented in detail
lsewhere [20,34]. DCs were generated from periph-
ral blood-derived CD14 monocytes as described
able 1. HLA Class I Typing of Various Donors Used in this Study*
Donors HLA-A HLA-B HLA-C
#1 A*01, A*24 B*07, B*08 Cw*07
#2
A*29, A*3001/
3014L/3015 B*1302/1308, B*44 Cw*06
#1 A*01, A*25 B*18, B*15 —
#2 A*03, A*32 B*07, B*08 Cw*07
#3 A*03 B*07, B*15 Cw*03, Cw*07
#4 A1, A3 B7, B62 Cw3, Cw7
#5 A*11, A*32 B*35, B*44 Cw*04, Cw*05Typing was performed serologically or by low-resolution PCR.
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Promiscuity of AlloHLA-restricted miHA-specific T Cells 153reviously [35]. After 6 d of culture, DCs were mat-
rated by overnight culture in the presence of 100
/mL TNF- (Peprotech, London, United King-
om), 5 ng/mL IL-1 (Peprotech), 150 ng/mL IL-6
Peprotech), 1 g/mL prostaglandin E2 (Sigma-Al-
rich, Zwijndrecht, Netherland), and 800 U/mL GM-
SF (Novartis Pharma BV, Arnhem, the Nether-
ands).
LA-A2/miHA Complex Coating on DCs
Mature DCs were incubated sequentially with bi-
tinylated mouse anti-human CD1a (Serotec, Oxford,
nited Kingdom), anti-human HLA class I (BD Bio-
ciences, Amsterdam, the Netherlands), anti-human
LA-DR (BD Biosciences), or anti-human CD45 an-
ibodies (BD Biosciences; 3 g/106 DCs), and with
rimeric streptavidin-coupled HLA-A2/miHA com-
lexes (5.64 g/106 DCs) for 60 min at 4°C in 100 L
BS per 106 DCs. DCs were washed with PBS after
ach incubation step. HLA-A2/miHA density of com-
lex-coated DCs was validated by staining with a con-
ormation-dependent HLA-A2 FITC-conjugated
ouse antibody (BD Pharmingen) before use.
eneration of HLA-A2/HA-1-specific T Cells using
utologous HLA-A2/HA-1 Complex-coated DCs
rom HLA-A2neg Donors
PBMCs were depleted of various cell subsets using
D4, CD14, CD16, and CD19 magnetic beads
Miltenyi GmBH, Bergisch Gladbach, Germany) ac-
ording to the supplier’s protocol. The remaining
D8 cell fractions were stimulated with irradiated
30 Gy) autologous HLA-A2/HA-1 complex-coated
Cs or with irradiated (30 Gy) alloHLA-A2pos HA-1
eptide-pulsed DCs, in the presence of autologous
rradiated (30 Gy) CD4 Th cells at a CD8:DC:CD4
:1:0.5 responder ratio in Iscove modiﬁed Dulbecco
edium (IMDM) containing 10% pooled human se-
um (HS), 1 U/mL IL-12 (R&D Systems, Minneap-
lis, Minn), and 2 Cetus units (cU)/mL IL-2 (Cetus,
meryville, Calif). The CD8 T cell lines were re-
timulated every 7 d with the same irradiated stimu-
ators and CD4 Th cells. IL-2 (25 cU/mL) was
dded 24 h after each restimulation.
irect Isolation and Culture of
LA-A2/HA-2-specific T Cells from PBMCs
The protocol used for detection of miHA-speciﬁc
cells in PBMCs was described previously [36].
rieﬂy, PBMCs from healthy multiparous female
lood donors were depleted of various cell subsets
sing CD4, CD14, CD16, and CD19 magnetic beads
Miltenyi GmBH). Depleted fractions were stained
ith PE-conjugated HA-2A2 tetramers and subse-
uently with CD45RO-FITC (BD Biosciences) and
D8-allophycocyanin (-APC) conjugated antibodies wBD Biosciences). HA-2A2 tetramer binding CD8
ells were isolated on a FACS Vantage cell sorter
Becton Dickinson, San Jose, CA) using a double-sort
rotocol. First, cells were enriched for HA-2A2 tet-
amer- and CD8 antibody-binding cells using the “en-
ich mode.” The enriched fraction was then reana-
yzed and immediately resorted using the more
tringent “normal-R” mode. Double FACS-sorted
ells were expanded in the presence of 5  104 irra-
iated (30 Gy) autologous PBMCs, 1% phytohemag-
lutinin (Murex, Dartford, United Kingdom), and 30
U/mL IL-2 (Cetus) in IMDM containing 10% HS.
For 2 donors, the enriched fraction was stained
ith relevant tetramers and resorted according to a
single cell per well” protocol. The resulting T cell
lones were expanded in the presence of random blood
onor-derived 5  104 irradiated (30 Gy) PBMCs and
 103 irradiated (50 Gy) EBV-transformed lympho-
lastoid cell lines (EBV-LCLs), 1% leukoagglutinin
Sigma-Aldrich), and 30 cU/mL IL-2 in IMDM con-
aining 10% HS.
eneration of Artificial Antigen-presenting
onstructs
The aAPCs were prepared as described previously
34]. In brief, polystyrene sulphate latex beads (Inter-
acial Dynamics, Portland, Ore) were incubated se-
uentially with streptavidin (10 g/107 beads; Molec-
lar Probes), recombinant human CD54/Fc-chimera
0.5 g/107 beads; R&D Systems), and CD80/
c-chimera (0.25 g/107 beads; R&D Systems), 1%
uman albumin (Sanquin, Amsterdam, the Nether-
ands), and biotinylated HLA-A2/miHA complexes (2
g/107 beads).
unctional Assays
Proliferation was determined by coculturing 5 
04 irradiated (30 Gy) stimulator cells with 2.5  104
esponder T cells for 48 h. The cultures were then
abeled with 1.0 Ci 3H-thymidine for 16 h, and
H-thymidine incorporation was measured using liq-
id scintillation counting. Cytotoxicity was evaluated
n a chromium release assay by incubating 2500 chro-
ium 51-labeled target cells with serial dilutions of
ffector T cells for 4 h. Supernatants were harvested
or gamma counting: percent speciﬁc lysis  (experimen-
al release  spontaneous release)/(maximal release 
pontaneous release)  100%. Results are shown for an
ffector:target ratio of 10:1 unless stated otherwise.
roliferation and cytotoxicity assay results are ex-
ressed as the mean of duplicate samples. Error bars
epresent SEMs.
IFN- cytokine secretion was measured by stim-
lating 1  105 T cells with aAPCs or with natural
timulators (EBV-LCLs) for 4 h. Responding T cells
ere identiﬁed using the IFN- Secretion Assay Cell
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L. E. M. Oosten et al.154nrichment and Detection Kit (PE*, Miltenyi Biotec)
ccording to the manufacturer’s instructions. All ﬂow
ytometric analyses were performed on a FACSCali-
ur with Cellquest software (Becton Dickinson, San
ose, Calif). Gates were set on vital lymphocytes ac-
ording to their typical forward- and side-scattering
haracteristics. If samples were stained with multiple
etramers, molar ratios were equalized. Results are
isplayed as mean ﬂuorescent intensity.
ESULTS
timulation of miHA-specific T Cells by
LA-A2/miHA Complex-coated DCs
HLA-A2/miHA complex-coated DCs were gener-
ted by coupling HLA-A2/miHA complexes via a
inker antibody to cell surface molecules expressed by
Cs (see Methods). Four different antibodies were
nalyzed for their capacity to anchor HLA-A2/miHA
rimers to the DC cell surface: anti-CD1a, anti-CD45,
nti-HLA class I, and anti-HLA-DR. Linkage
igure 1. Stimulation of miHA-speciﬁc T cells with HLA-A2/miH
nd HLA-A2/miHA complex-coated HLA-A2neg DCs (right) b
, Cytolytic activity by an HA-1-speciﬁc T cell clone (ﬁlled diamon
oated with various amounts of HLA-A2/HA-1 or HLA-A2/HA-2
A-1 or HA-2 peptides (open symbols). C, A polyclonal HA-1-
estimulated 2 times with autologous HLA-A2/HA-1 complex-coate
ytolytic activity directed against HLA-A2neg EBV-LCLs (open ba
ested in parallel on days 0 and 14.hrough HLA-DR was associated with the highest and
ost prolonged complex binding and displayed the
trongest capacity to stimulate miHA-speciﬁc HLA-
2-restricted T cells (data not shown). FACS analysis
ith a conformation-dependent HLA-A2-speciﬁc anti-
ody showed that HLA-A2/miHA complexes anchored
ia HLA-DR to HLA-A2neg DCs were coated at densi-
ies equal to natural HLA-A2 levels expressed by HLA-
2pos DCs (Figure 1A). We used HLA-A2/miHA com-
lexes coupled via HLA-DR for further studies.
The capacity of HLA-A2/miHA complex-coated
Cs to efﬁciently elicit cytolytic responses by HLA-
2-restricted miHA-speciﬁc T cells was analyzed in a
ytotoxicity assay (Figure 1B). An HA-1- and an HA-
-speciﬁc T cell clone effectively lysed HLA-A2neg
Cs coated with HLA-A2/HA-1 or HLA-A2/HA-2
omplexes in a dose-dependent manner. At higher
oating densities, HLA-A2/miHA complex-coated
Cs were lysed to the same extent as HLA-A2pos
iHA peptide-pulsed DCs. HLA-A2neg DCs coated
ith irrelevant HLA-A2/miHA complexes, unbound
plex-coated DCs. A, HLA-A2 expression by HLA-A2pos DCs (left)
ﬁlled histogram) and after (open histogram) complex coating.
d an HA-2 speciﬁc T cell clone (ﬁlled squares) in response to DCs
xes (micrograms per 106 DCs) or to HLA-A2pos DCs pulsed with
T cell line generated from an HLA-A2pos HA-1neg donor was
HA-1A2 tetramer binding was determined on days 0, 7, and 14. The
LA-A2pos EBV-LCLs naturally expressing HA-1 (ﬁlled bars) wasA com
efore (
ds) an
comple
speciﬁc
d DCs.
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Promiscuity of AlloHLA-restricted miHA-specific T Cells 155LA-A2/miHA complexes, or HLA-A2/miHA com-
lexes added together with HLA-A2neg DCs in the
bsence of linking HLA-DR antibodies were not lysed
data not shown). Further, HLA-A2/HA-1 complex-
oated DCs effectively enriched an HA-1-speciﬁc
cell line for functional HA-1-speciﬁc T cells upon 2
ounds of stimulation (Figure 1C). Collectively, these
ndings demonstrate that HLA-A2/miHA complex-
oated DCs can be used as efﬁcient stimulators for
iHA-speciﬁc T cells.
eneration of AlloHLA-A2-restricted
A-1-specific T Cells from HLA-A2neg Male
onors using Autologous HLA-A2/HA-1
omplex-coated DCs
HLA-A2/HA-1 complex-coated DCs were used as
PCs for the generation of HA-1-speciﬁc CD8 T
ells from HLA-A2neg male donors M#1 and M#2
Figure 2A,B). In parallel, we stimulated CD8T cells
rom donors M#1 and M#2 with allogeneic HLA-
2pos DCs pulsed with HA-1 peptide (Figure 2C,D).
ll 4 T cell lines were restimulated at weekly intervals
see Methods) and expanded well, resulting in 3- to
-fold increases in absolute cell numbers on day 21
igure 2. Generation of polyclonal alloHLA-A2/HA-1 speciﬁc T ce
A, C) and M#2 (B, D) were stimulated with autologous HLA
eptide-pulsed DCs (C, D). HA-1A2 tetramer binding and cytolytic
open bars) or HA-1 peptide-pulsed T2 cells (ﬁlled bars) were determin
y T cells stimulated with HLA-A2/HA-1 complex-coated DCs but not by Tdata not shown). Emerging HLA-A2/HA-1-speciﬁc
cells were monitored with HA-1A2 tetramers and
ontrol tetramers comprising an irrelevant peptide.
fter 20 d of culture, HLA-A2/HA-1-speciﬁc T cells
ould be detected within the bulk T cell cultures of
onors M#1 and M#2 stimulated with autologous
LA-A2/HA-1 complex-coated DCs. The frequency
f tetramer binding T cells within the T cell line
enerated from donor M#1 increased with additional
ounds of stimulation, whereas percent tetramer bind-
ng T cells remained constant in the T cell culture of
onor M#2. Patterns of tetramer staining were differ-
nt for each alloreactive T cell line, suggesting that
istinct subsets of expanded T cells bound tetramers
ith different avidities. We could not detect HA-1A2
etramer binding cells in T cell lines generated with
llogeneic HA-1 peptide-pulsed HLA-A2pos DCs.
The cytolytic activity of all 4 T cell lines was com-
ared after 5 wk of continuous culture. The M#1 and
#2 T cell lines stimulated with autologous HLA-A2/
A-1 complex-coated DCs effectively lysed transporter
ssociated with antigen-processing (TAP)-deﬁcient T2
ells pulsed with HA-1 peptide, whereas unpulsed T2
ells were less efﬁciently lysed. These results suggested
HLA-A2neg donors. CD8 T cells from HLA-A2neg donors M#1
A-1 complex-coated DCs (A, B) or with alloHLA-A2pos HA-1
(effector:target ratio, 80:1) directed against TAP-deﬁcient T2 cells
5 rounds of stimulation. A-D show preferential recognition of HA-1A2lls from
-A2/H
activity
ed aftercells stimulated with HLA-A2pos HA-1 peptide-pulsed DCs.
t
b
c
s
p
r
S
A
l
w
D
f
r
w
i
r
a
ﬁ
i
s
F
t
a
E
t
H
a
r
L. E. M. Oosten et al.156hat T cell lines generated from donors M#1 and M#2
y autologous HLA-A2/HA-1 complex-coated DCs
ontained T cells with alloHLA-A2-restricted HA-1-
peciﬁc reactivity. T cell lines generated with HA-1
eptide-pulsed allogeneic DCs displayed alloHLA-A2
eactivities of undetermined speciﬁcity only.
pecificity of In Vitro Generated
lloHLA-A2-restricted HA-1-specific T Cells
To further analyze the speciﬁcities of the al-
oHLA-A2-restricted HA-1-speciﬁc T cells generated
igure 3. Speciﬁcity of polyclonal HA-1A2 tetramer binding T ce
etramer binding CD8 T cells isolated from donor M#1 before an
nd tetramer-nonbinding (open bars) CD8 T cells isolated from
BV-LCLs exogenously pulsed with HA-1 peptide, HLA-A2pos EBV
arget inhibition of the cytolytic activity of the HA-1A2 tetramer bi
A-1 peptide (ﬁlled bars). Unlabeled T2 pulsed with HA-2 or HA
t a 10:1 cold:hot ratio. C, IFN- production by HA-1A2 tetramer b
esponse to aAPCs presenting a single set of HLA-A2/HA-1 or HLA-A2/ith autologous HLA-A2/HA-1 complex-coated
Cs, we isolated the HA-1A2 tetramer binding T cells
rom the polyclonal M#1 T cell line by ﬂow cytomet-
ic cell sorting. The HA-1A2 tetramer binding T cells
ere enriched 26% to 	90% (Figure 3A). The spec-
ﬁcity of the HA-1A2 tetramer binding and nontet-
amer binding FACS-sorted fractions were assessed in
cytotoxicity assay (Figure 3B, left panel). Lysis pro-
les of the HA-1A2 tetramer binding T cells showed
ncreased recognition of HLA-A2pos EBV-LCLs irre-
pective of the presence of HA-1, but decreased rec-
erated from donor M#1. A, tetramer binding proﬁles of HA-1A2
sorting. B, Left, Cytolytic activity of tetramer binding (ﬁlled bars)
M#1 directed against HLA-A2pos HA-1neg EBV-LCLs, the same
s naturally expressing HA-1 or HLA-A2neg EBV-LCL. Right, Cold
D8 T cells from donor M#1 in response to T2 cells pulsed with
ide, or HLA-A2pos HA-1neg EBV-LCLs were used as cold targets
CD8 T cells from donor M#1 or a HA-1-speciﬁc T cell clone inlls gen
d after
donor
-LCL
nding C
-1 pept
indingHA-1 complexes.
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Promiscuity of AlloHLA-restricted miHA-specific T Cells 157gnition of HLA-A2neg EBV-LCLs. Apparently, the
A-1A2 tetramer-based ﬂow cytometric cell sorting
rocedure had enriched for broad alloHLA-A2-reac-
ive T cells but not for HLA-A2/HA-1-speciﬁc T
ells. The lack of HA-1 peptide-speciﬁc lysis could not
e attributed to increased NK reactivity because HLA
lass Ineg target cells (K562) were not lysed (data not
hown).
Broad alloHLA-reactive T cells staining with mul-
iple tetramers irrespective of peptide have been de-
cribed before [15,17]. The HA-1A2 tetramer binding
cells did, however, not bind irrelevant peptideA2
etramers or lysed T2 cells pulsed with these irrelevant
eptides (data not shown). Cold target inhibition stud-
es showed that lysis of HLA-A2pos targets could be
nhibited by addition of unlabeled T2 cells pulsed with
A-1 peptide or by addition of HLA-A2pos/HA-1neg
BV-LCLs, but not by addition of T2 cells pulsed
ith irrelevant HA-2 peptide (Figure 3B, right panel).
hese ﬁndings suggest that the HA-1A2 tetramer
inding T cells generated from donor M#1 recognize
A-1, but also other undeﬁned peptides presented
n the context of HLA-A2, in a peptide-dependent
anner.
To further validate this supposition, we analyzed
he capacity of the HA-1A2 tetramer binding T cells to
yse T2 cells pulsed with fractions from an HPLC-
eparated HLA-A2-derived peptide pool. Although
ach of these fractions contains numerous peptides,
nly 4 of 50 fractions were recognized (data not
hown). Another possible explanation for the presence
f the HA-1A2 tetramer binding T cells of undeﬁned
ntigen speciﬁcity could be peptide-independent T
ell recognition of recombinant HLA-A2/peptide
omplexes due to slight variations in the folding of the
ecombinant HLA-A2 molecules. The presence of
igure 4. Left, Speciﬁcity of polyclonal HA-1A2 tetramer binding
etramer binding CD8 T cells isolated from donor M#2 after
etramer-nonbinding (open bars) CD8 T cells isolated from do
BV-LCLs exogenously pulsed with HA-1 peptide, HLA-A2pos EBV-LCuch T cells within the M#1-derived HA-1A2 tetramer
inding T cell population could confound our ﬁnd-
ngs. To exclude this possibility, we used aAPCs
oated with HLA-A2/HA-1 or HLA-A2/HA-2 com-
lexes to stimulate the HA-1A2 tetramer binding T
ells from donor M#1. An established HLA-A2-re-
tricted HA-1-speciﬁc T cell clone was tested in par-
llel (Figure 3C). The self HLA-A2- and the al-
oHLA-A2-restricted T cells from donor M#1 only
roduced IFN- when stimulated with HLA-A2/HA-
-expressing aAPCs, whereas nonspeciﬁc recognition
f HLA-A2/HA-2 expressing aAPCs was not ob-
erved.
The T cell line generated from donor M#2 was
nriched as described for donor M#1 and cytolytic
unction and speciﬁcity in response to various target
ells were analyzed (Figure 4). Despite poor HA-1A2
etramer binding, the FACS-sorted T cell population
isplayed increased lytic activity of HLA-A2pos EBV-
CLs pulsed with HA-1 peptide. These results imply
hat the HLA-A2/HA-1-speciﬁc T cells obtained
rom donor M#2 are of low avidity but nonetheless
isplay selective HA-1-speciﬁcity.
irect Isolation of HLA-A2/HA-2-specific T Cells
rom Peripheral Blood of Multiparous Female
onors
The presence of circulating alloHLA-A2/HA-2-
peciﬁc T cells in peripheral blood was analyzed in 5
LA-A2neg multiparous female donors (F#1 to F#5)
ho had delivered 1 HLA-A2pos HA-2pos child. We
sed the miHA HA-2 because of the high frequency of
he HA-2V immunogenic allele in the Caucasian pop-
lation [37]. HA-2A2 tetramer binding T cells were
solated from CD8-enriched PBMC fractions by
ACS sorting. After the ﬁrst enrichment sort, the
generated from donor M#2. tetramer binding proﬁle of HA-1A2
. Right, Cytolytic activity of tetramer binding (ﬁlled bars) and
#2 directed against HLA-A2pos HA-1neg EBV-LCLs, the sameT cells
sorting
nor MLs naturally expressing HA-1 or HLA-A2neg EBV-LCL.
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L. E. M. Oosten et al.158A-2A2 tetramer binding proﬁles varied signiﬁcantly
rom hardly any tetramer binding CD8 T cells to
inding of a clear population of CD8bright T cells.
ACS-sorted populations were nonspeciﬁcally ex-
anded in vitro, omitting HA-2-speciﬁc stimulation
see Methods). After 28 d of culture, only the T cell
opulations sorted from donors F#1 and F#5 dis-
layed HA-2A2 tetramer binding cells. The T cell
ulture obtained from donor F#1 contained 	90% T
ells that selectively bound HA-2A2 tetramers without
ppreciable crossreactivity with irrelevant peptideA2
etramers (Figure 5A). However, HLA-A2pos EBV-
CLs pulsed with HA-2 peptide or naturally express-
ng HA-2 were not lysed. Thus, the T cells obtained
rom donor F#1 were of low avidity or not HA-2
peciﬁc, despite their prominent tetramer binding
roﬁle.
Within the T cell culture established from donor
#5, 5%-8% of cells bound HA-2A2 tetramers in ad-
ition to HA-1A2 and CMVA2 tetramers (Figure 5B).
hese tetramers presumably bind the same T cell
opulation because the percentage of tetramer bind-
igure 5. Direct isolation of alloHLA-A2/HA-2-speciﬁc T cells fro
D8 cells obtained from the peripheral blood of HLA-A2neg par
A-2A2 tetramer binding cells. The rectangles represent the gate se
MVA2, HYA2) of CD8 T cells derived from donors F#1 or F#5 a
cells directed against HLA-A2pos HA-1neg EBV-LCLs, the sa
BV-LCL. C, Left, Staining of CD8 T cells from donor F#5
opulation from donor F#5 with HA-1A2 tetramer-APC and HA
etramer-PE (right). A single subset of the donor F#5-derived T cell
fﬁnities.ng T cells did not increase when the various tetramers
ere combined (Figure 5C, left panel). Interestingly,
he T cell population did not bind HYA2 tetramers,
ndicating that the alloHLA-A2 recognition of these
cells was not peptide independent. When the T cell
opulation was stained with a mixture of HA-1A2 and
A-2A2 tetramers, only the HA-1A2 tetramers were
ound, indicating a higher TCR avidity for HLA-A2/
A-1 than for HLA-A2/HA-2 (Figure 5C, center
anel). TCR avidity for HLA-A2/HA-1 and HLA-A2/
MV (Figure 5C, right panel) appeared to be similar,
espite the absence of sequence homology between
hese peptides. The T cell line generated from donor
#5 was tested for alloHLA-A2 speciﬁcity in a cyto-
oxicity assay. The T cells lysed HLA-A2pos target
ells independently of the presence of HA-2, thus
nderlining the promiscuity of the T cells isolated
rom donor F#5 by HA-2A2 tetramers.
To further investigate the apparent different al-
oHLA-A2-reactive T cells populations present in do-
ors F#1 and F#5, we cloned HA-2A2 tetramer bind-
ng T cells by single-cell-per-well FACS sorting. The
A-A2neg parous female donors F#1 and F#5. A, B, Left, Analysis of
ale donor F#1 or F#5 after a ﬁrst enrichment sort for CD8 and
e second sort. Center, tetramer binding proﬁles (HA-2A2, HA-1A2,
d of nonspeciﬁc expansion. Right, Cytolytic activity of these CD8
V-LCLs exogenously pulsed with HA-1 peptide or HLA-A2neg
oled tetramers. Center and right, Staining of the CD8 T cell
tramer-PE (center) or with HA-1A2 tetramer-APC and CMVA2
tion binds the HA-2A2, HA-1A2, and CMVA2 tetramers with varyingm HL
ous fem
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Promiscuity of AlloHLA-restricted miHA-specific T Cells 159orted T cells were expanded and tested for their
apacity to bind HA-2A2, HA-1A2, and HYA2 tetram-
rs and to produce IFN- after ligand-speciﬁc stimu-
ation. Stimulators were aAPCs presenting a single set
f HLA-A2/HA-2, HLA-A2/HA-1, or HLA-A2/HY
omplexes or various EBV-LCLs. Table 2 summa-
izes the results. Three different types of T cell clones
ere generated from donors F#1 or F#5, ie, T cells
hat bound none of the tetramers tested (I-28, I-51), T
ells that bound HA-2A2 tetramers and HA-1A2 and/or
YA2 tetramers (I-3, I-45, I-53, I-60), and T cells that
ound HA-2A2 tetramers only (I-4). The strength of
etramer binding correlated with the capacity of the
arious T cell clones to produce IFN- in response to
he various aAPCs. However, most T cell clones failed
o discriminate between HA-2 peptide-pulsed or con-
rol unpulsed HLA-A2pos/HA-1, HA-2, and HYneg
BV-LCLs. Only T cell clone I-4 appeared to be
LA-A2/HA-2 speciﬁc in the latter assay and was
ubsequently tested in a cytotoxicity assay. Despite
A-2-speciﬁc tetramer binding (Figure 6A) and
FN- production (Figure 6B), T cell clone I-4 lysed
LA-A2pos/HA-2pos and HLA-A2pos/HA-2neg EBV-
CLs, but not HLA-A2neg EBV-LCLs or HLA
lass Ineg target cells (Figure 6C).
Collectively, these results show that in vitro expo-
ure through stimulation with artiﬁcial alloHLA-A2/
iHA complexes and in vivo exposure to natural al-
oHLA-A2/miHA complexes through pregnancy yield
cells sharing functional characteristics. These T cell
opulations contain alloHLA-A2-restricted miHA-
peciﬁc T cells with low TCR avidity or alloHLA-A2-
estricted T cells that seem to be miHA speciﬁc, but
rossreact with unknown peptides naturally presented
y HLA-A2.
ISCUSSION
In this study we evaluated 2 different strategies to
able 2. Functional Characteristics of T Cell Clones Generated from P
Tetramer-staining Intensity*
HA-2A2 HA-1A2 HYA2 A2/HA-2
#1 I-3  /  0
I-4    72
I-28    0
I-29    0
I-45   / 74
#5 I-51    0
I-53 /   0
I-60  /  34
Staining levels were measured in mean ﬂuorescence units and com
miHA-speciﬁc T cell clones (, equal staining; , no staining;
IFN- production was measured as percent live CD8 cells prodenerate alloHLA-A2-restricted T cells speciﬁc for Hhe miHA HA-1 or HA-2 for the purpose of cellular
doptive immunotherapy after putative HLA-A2-mis-
atched SCT. Aiming at clinical applicability, we
hose isolation and expansion procedures meeting
ood manufacturing practice requirements. Both
trategies used recombinant HLA-A2/miHA com-
lexes as sole allogeneic antigens to isolate or expand
lloHLA-A2-restricted miHA-speciﬁc T cells derived
rom PBMCs from HLA-A2neg individuals. Neither
timulation with HLA-A2/miHA complex-coated
Cs nor direct isolation from peripheral blood using
LA-A2/miHA tetramers yielded T cells displaying
trict miHA-speciﬁc reactivity despite selective tet-
amer-staining proﬁles. Instead, we obtained miHA-
peciﬁc T cells of low avidity or T cells displaying
elective but not miHA-speciﬁc cytolytic capacities.
he latter T cells were found at both the polyclonal
nd clonal levels. We conclude that promiscuity of the
lloHLA-A2-reactive T cell repertoire hampers the
se of HLA/miHA multimers as tools for the gener-
tion of alloHLA-A2-restricted HA-1- or HA-2-spe-
iﬁc T cells in a reproducible, safe, and clinically
pplicable manner.
Previous studies have described in vitro generation
f alloHLA-restricted antigen-speciﬁc cytotoxic T
ells [14-18]. However, many of these alloHLA-re-
tricted T cells were of low avidity or displayed addi-
ional reactivities against antigens other than the orig-
nal target antigen [15-18]. These reactivities may
ave been due to the use of alloHLA-A2pos cells ex-
ressing multiple potential allogeneic antigens such as
PCs. In our study, we successfully applied and report
or the ﬁrst time the use of autologous HLA-A2neg
Cs as APCs. The DCs express HLA-A2/miHA
omplexes that are bound to the APC surface via
nti-HLA-DR antibodies. Similarly, Savage et al [14]
pplied antibodies that speciﬁcally bind to the CD20
olecules expressed by B cells. We compared anti-
odies speciﬁc for CD1a, CD45, HLA class I, and
emale Donors
IFN- Production†
PCs
EBV-LCLs
/HA-1 A2/HY
HLA-A2pos HA2neg
HLA-A2negpHA-2 pHA-2
6 4 0 0 0
0 0 14 99 10
0 0 0 0 0
0 0 0 0 0
1 8 91 93 0
0 0 1 1 1
8 NT 25 24 0
14 2 97 97 2
with tetramer staining of established cytolytic HLA-A2-restricted
ntermediate staining).
FN-.arous F
aA
A2
pared
/, iLA-DR for their capacity to anchor stimulatory
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L. E. M. Oosten et al.160igand to DCs. The antibodies were evaluated in
ACS analyses, cytotoxicity assays, and expansion
rocedures using established ligand-speciﬁc T cell
ines and clones (data not shown). The comparative
ata showed that DCs anchoring ligand via HLA-DR
ere the most stimulatory for ligand-speciﬁc T cell
ines and clones. Although this artiﬁcial form of anti-
en presentation could theoretically affect T cell func-
ion, we observed no loss of T cell cytotoxicity or
peciﬁcity for any antibody tested.
A possible explanation for the high frequency of
eptide-selective but not peptide-speciﬁc T cells ob-
igure 6. Speciﬁcity of HA-2A2 tetramer binding T cells derived
rom donor F#1. A, HA-2A2 and HA-1A2 tetramer binding by T cell
lone I-4, derived from donor F#1 using a single-cell-per-well
orting procedure. B, IFN- production of T cell clone I-4 in
esponse to aAPCs presenting a single set of HLA-A2/HA-2 (left)
r HLA-A2/HA-1 (right) complexes. C, Cytolytic activity of T cell
lone I-4 in response to varying EBV-LCLs displaying HA-2-
ndependent recognition of HLA-A2pos target cells despite HA-1-
peciﬁc tetramer binding and IFN- production shown in A and B.erved in the present study is the application of linked oLA-A2/HA-1 complexes to mature DCs. High avid-
ty alloHLA-A2-restricted HA-1-speciﬁc T cells have
een generated from the same HLA-A2neg donors
sed in this study after limiting dilution and extensive
esting [13]. The use of the latter optimal APCs as
timulator cells may have inadvertently expanded low
fﬁnity or cross-reactive T cells naturally present in
he alloHLA-reactive T cell repertoire, thereby ham-
ering the induction of miHA-speciﬁc T cells. Alter-
atively, environmental triggers may have affected the
onors’ alloHLA-reactive T cell repertoires in the
ime frame between the 2 studies. The association
etween “heterologous” antiviral T cell responses and
lloHLA reactivity has previously been documented
38].
Our approach to isolate alloHLA-A2-restricted
iHA-speciﬁc T cells was based on previous studies
howing the feasibility of isolating alloHLA-A2-spe-
iﬁc T cells by tetramer selection [15,17]. We chose
emale HLA-A2neg donors who had delivered 1
LA-A2pos HA-2pos child. miHA-mismatched preg-
ancy has been shown to immunize the mother, re-
ulting in fetal miHA-speciﬁc T cells in the maternal
irculation [36]. In that study, mother and child
hared the HLA-A2 allele. In the HLA-A2-mis-
atched setting used in this study, only low avidity or
ross-reactive T cells could be isolated, despite the use
f the same isolation and culture protocols. Thus, our
ndings may point to a qualitative and/or quantitative
ifference between T cells generated in a setting
herein the HLA restriction molecule for miHA pre-
entation is shared versus not shared.
Over the past decade, notions on the nature of the
CR-HLA/peptide interaction have changed consid-
rably. Although this interaction was previously
hought to be highly speciﬁc and restricted to a single
LA/peptide combination, evidence is emerging that
CR promiscuity is a common and important aspect
f TCR recognition [39-42]. The balance between
peciﬁcity and promiscuity likely represents a compro-
ise between the necessity to ensure functional rec-
gnition of a large number of possible pathogenic
pitopes and the need to avoid harmful autoreactivi-
ies. AlloHLA reactivity arises from the promiscuity of
T cell pool originally selected for reactivity to self-
LA molecules. During T cell maturation in the
hymus, T cells are negatively selected (deleted) if they
ecognize ubiquitously expressed peptides in the con-
ext of self-HLA with high afﬁnity. Selection for re-
ctivity with peptides presented by alloHLA mole-
ules does not occur. The alloHLA-reactive T cell
epertoire is therefore large, up to 10% of the total
eripheral T cell repertoire [43,44], and not very spe-
iﬁc in terms of antigen recognition. Peptide-inde-
endent, peptide-dependent, and peptide-speciﬁc rec-
gnitions have all been documented [15,17,45-53].
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Promiscuity of AlloHLA-restricted miHA-specific T Cells 161The strategy of generating immunotherapeutic T
ells recognizing peptides presented by alloHLA mol-
cules is based on the assumption that the speciﬁcities
f individual T cells are comparable for alloHLA/
eptide complexes and self-HLA/peptide complexes
13]. Recombinant tetrameric HLA/peptide com-
lexes bind to self-HLA-restricted peptide-speciﬁc T
ells with high speciﬁcity [54] and tetramer binding
sually correlates with peptide-speciﬁc cytolytic and
ytokine-secreting functions [32,55]. Although HLA/
eptide tetramers have also been used to visualize and
solate peptide-speciﬁc alloHLA-restricted T cells
15,17], both studies reported discrepancies between
etramer binding and cytolytic function. In line with
hese latter reports, we could not rely on HLA-A2/
iHA tetramer binding as a selective tool to distin-
uish between alloHLA-restricted peptide-speciﬁc T
ells and peptide-nonspeciﬁc T cells. Our results in-
icate that T cells recognize alloHLA/peptide and
elf-HLA/peptide complexes with different speciﬁci-
ies and avidities. Promiscuity of miHA-speciﬁc T
ells seems to occur predominantly in the alloHLA-
estricted setting. The presence of such cross-reactiv-
ties seriously hampers the application of alloHLA-
estricted T cells for adoptive immunotherapy because
hey may be detrimental to the patient. Naturally, our
onclusions are exclusively based on in vitro analyses and
o not allow direct interpretation for the in vivo situa-
ion. However, the underlying isolation and expansion
rotocols were executed as a feasibility study for the
urpose of cellular adoptive immunotherapy in the
LA-mismatched SCT setting.
In summary, we show that the alloHLA-A2-re-
tricted T cell repertoire is highly promiscuous. Ex-
osing such T cells to single alloHLA/peptide com-
lexes does not prevent the parallel induction of
road alloHLA-A2 reactivities. Moreover, polyclonal
lloHLA-A2-restricted cross-reactive T cells cannot
e readily distinguished from miHA-speciﬁc T cells
y currently available technologies. Generation of
lloHLA-A2-restricted hematopoietic system-speciﬁc
cells requires laborious and time-consuming limit-
ng dilution protocols and extensive in vitro testing on
recipient’s cells before such T cells can be safely
pplied in the clinical setting of HLA-mismatched
CT.
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